Year: 2017

The gastrointestinal wall is a significant site of first-pass metabolism for oral drugs, which is commonly associated with CYP450 and...

If you have concerns about how your compound may affect UDP-glucuronosyltransferase (UGT) induction and/or inhibition when combined with other therapeutic...

If you are looking for enzymatic in vitro tools for drug metabolism, reaction phenotyping or metabolite generation using a pig model, you may find these newly...

XenoTech is committed to furthering the knowledge surrounding hepatic diseases, which affects one out of four people worldwide, such as...

As you may have heard, XenoTech was issued U.S. Patent No. 9,642,355 for the “CRYOPRESERVATION OF CELLS AND SUBCELLULAR FRACTIONS” for its CryostaX® hepatocytes. The...

XenoTech has appointed Joanna Barbara, Ph.D., as Vice President of Scientific Operations and Brian Ogilvie, Ph.D., as Vice President of Scientific...

A new guide outlining our IgG Catabolism Protocol as well as Lysosome and Tritosome Technical Tips is now available for those evaluating lysosomal stability...

Transporters have become increasingly important in drug development due to the major role they play in absorption, distribution and excretion of...

After our nomination in late 2016, XenoTech has been named the Best for Pharmaceutical Safety Testing in the 2017 Biotechnology...

XenoTech is adding human and minipig to the company’s list of species with dermal subcellular fractions available as standard test systems for the development...